Explore life science & biotech companies in Oxford, home to one of the world's leading biotechnology and life science clusters.
Antisense oligonucleotide therapies for TUBB4A-associated leukodystrophies
SynaptixBio is a biotechnology company developing antisense oligonucleotide therapies for severe inherited leukodystrophies. Its lead programme targets TUBB4A-associated hypomyelinating disorders, including hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). The approach uses synthetic…
3D genomics platform for blood-based clinical diagnostics and precision medicine
Oxford BioDynamics develops blood-based diagnostic tests and precision medicine tools using its proprietary 3D genomics platform. The technology analyses chromosome conformation to identify epigenomic biomarkers linked to disease, prognosis and treatment response. Commercial products include tests for immune…
Needle-free solid dose vaccine formulation and delivery platform
aVaxMed Limited is a UK biotech developing the aVaxziPen platform, a proprietary needle-free, thermally stable, solid dose vaccine delivery system. The technology encapsulates vaccine antigens into unit solid doses administered via a pen applicator, removing the need for needles and reducing cold chain requirements.…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its…
PCR platform enabling precision diagnostics on standard lab instruments
Signatur Biosciences is a biotechnology company developing a molecular diagnostic platform that encodes complex RNA gene expression signatures into single qPCR reactions. The technology enables precision diagnostics to be performed on standard laboratory instruments already present in clinical settings, removing…
Contract development and manufacture of nanofibrous biomaterials for medical devices
The Electrospinning Company designs, develops, and manufactures nanofibrous biomaterials for implantable medical devices and regenerative medicine applications. Using electrospinning technology, the company produces four proprietary membrane platforms: resorbable Mimetix, permanent Kalyptix, biosynthetic Symatix, and…
Enzyme-based platform for sustainable industrial chemical manufacture
HydRegen is a biotechnology company developing enzyme immobilisation platforms that replace heavy-metal catalysts in redox and hydrogenation reactions. The technology uses hydrogen gas to power NADH-dependent enzymes on carbon supports, enabling continuous flow processing of fine chemicals and active pharmaceutical…
T cell-based tuberculosis diagnostics and clinical laboratory testing services
Oxford Immunotec is an Abingdon-based diagnostics company developing, manufacturing, and supplying T cell-based diagnostic tests for infectious and immunological diseases. Its platform measures specific T cell immune responses to inform clinical diagnosis, with the T-SPOT.TB test for tuberculosis detection cleared by…
Specialty enzyme manufacturer serving food, diagnostics and pharmaceutical industries
Amano Enzyme Europe is the UK subsidiary of Japanese specialty enzyme manufacturer Amano Enzyme Inc, serving as its EMEA hub. The company supplies microbial enzymes for food and beverage processing, dietary supplements, pharmaceutical manufacturing and clinical diagnostics. Its UK laboratories support enzyme…
UK distributor of analytical instruments and laboratory equipment
ATG Scientific Limited is a distributor of laboratory instruments and equipment for analytical chemistry, life sciences, and materials characterisation laboratories across the UK, Ireland, and Europe. The company represents a portfolio of international manufacturers, supplying surface plasmon resonance instruments,…
TCR bispecific immunotherapies for cancer and infectious disease
Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases. The company's approach selectively depletes pathogenic T cell subsets that drive chronic inflammation, using precise targeting of disease-relevant membrane…
Pre-cancer intervention to prevent cancer before it develops
Omos Biosciences is an early-stage biotechnology company developing approaches to cancer prevention through intervention at the pre-cancerous stage, rather than treatment of established disease. The company's strategy builds on established precedents in early cancer prevention, such as polyp removal to prevent…
mRNA vaccine manufacturer and R&D partner
Moderna is a company developing and manufacturing mRNA-based medicines and vaccines across infectious disease, oncology and rare disease. Its UK Innovation and Technology Centre, opened at Harwell in September 2025, is the first facility in the UK capable of onshore mRNA vaccine manufacturing, with capacity for up to…
Autophagy-enhancing small molecule drugs for neurodegeneration and rare disease
Samsara Therapeutics is a drug discovery company developing first-in-class small molecule therapeutics that restore autophagy, the cellular process of degrading and recycling damaged proteins, which declines with age and is dysfunctional in multiple diseases. Its platform identifies and chemically optimises…
Next-generation viral vectors engineered for safer gene therapy delivery
Sandbox Bioscience is a biotechnology company developing next-generation viral delivery vectors for gene therapy. Founded by a team of virologists with extensive experience in gene therapy delivery systems and platform development, the company is engineering vectors designed to improve on existing market solutions…
Oncolytic virus platform for tumour-targeted cancer immunotherapy
Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform. Designed for systemic delivery, the platform selectively replicates within cancer cells to generate therapeutic payloads locally at the tumour site. The…
Clinical-stage developer of oncolytic immunotherapies for cancer treatment
Replimune is the UK research and development site of Replimune Group, a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its platform uses genetically engineered herpes simplex viruses to selectively replicate within and destroy tumour cells, releasing tumour antigens and…
Global medical technology company specialising in chronic condition management
Convatec is a global medical products and technologies company focused on chronic condition management. The group develops and manufactures advanced wound care dressings, ostomy care, continence care and infusion care products, including hydrofiber-based, antimicrobial and tissue-derived biomaterial wound dressings…
Full-service CRO delivering clinical trial and regulatory support services
Optimapharm is a contract research organisation providing clinical trial management and observational study services to pharmaceutical, biotech and medical device companies. The company supports trials from Phase I through Phase IV, offering regulatory affairs, medical writing, clinical monitoring, data management,…